Xifaxan Ibsd denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xifaxan ibsd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Uses Step Therapy for Xifaxan (rifaximin) in IBS-D

Step therapy — sometimes called "fail first" — requires patients to try and fail one or more formulary-preferred drugs before UHC will cover Xifaxan for IBS-D. UHC's step-therapy protocols for IBS-D typically require documented trials of less costly or generic alternatives. This denial is not a judgment that Xifaxan is wrong for you — it is a coverage-sequence rule. When prior required steps have already been completed (or are clinically contraindicated for this patient), step-therapy denials are among the most commonly reversed on appeal.

Many states also have step-therapy override laws requiring insurers to waive the step requirement when the required prior drug was tried and failed, is contraindicated, or is otherwise clinically inappropriate. Confirm whether your state's law applies to your plan type.

## Your Appeal Rights

• Internal appeal (ERISA §503): File a written internal appeal with documentation of prior step completion. Include specific dates and outcomes.
• Step-therapy exception: Most plans have a formal step-therapy exception process separate from (or combined with) the internal appeal. Request both simultaneously.
• External review (ACA §2719): If the internal appeal is denied, independent external review is available. File within the four-month window from the final internal denial.
• Expedited review: If delay would seriously harm health or the ability to regain function, request expedited processing.
• State step-therapy override: If your plan is a fully insured state-regulated plan (not a self-funded ERISA plan), check your state's step-therapy override statute.

## Documentation to Gather

1. Prior-step trial documentation — for every drug UHC's policy requires as a first step, provide dated pharmacy records, chart notes documenting the trial, and the specific reason it was stopped (lack of efficacy, adverse effect, intolerance). 2. Clinical contraindication letter — if a required prior step was not tried because it is clinically inappropriate for this patient, the prescriber must document the specific clinical reason in a signed letter. 3. Diagnosis confirmation — chart notes and ICD-10 code for IBS-D. 4. UHC step-therapy criteria — request UHC's current step-therapy protocol for Xifaxan/rifaximin in IBS-D; address each required step in the appeal. 5. FDA prescribing label — attach to document the approved indication. 6. Applicable guideline reference — the prescriber may cite the relevant professional society guideline organization (e.g., the applicable ACG guideline) supporting the clinical appropriateness of Xifaxan after step-therapy failure.

## Criteria-Mapping Structure

| UHC Step-Therapy Requirement | Documentation Provided | |---|---| | Step 1 drug trialed | Pharmacy record [date range], chart note [date], outcome | | Step 2 drug trialed or contraindicated | Pharmacy record or prescriber contraindication letter | | IBS-D diagnosis confirmed | Chart note [date], ICD-10 code |

If all required steps are documented, the appeal letter should open by stating that every prior step has been completed and attach the evidence before anything else.